The Top Biophama list is stable this time around; the only change was between CSL and Genzyme, and that was mainly due to the dramatic appreciation of CSL’s reporting currency, the Australian dollar. Scarily, the cumulative revenues of our Top 10 Biopharmas grew a mere 3% in 2010, compared to 4%, 14% and 16% in 2009, 2008 and 2007. That’s the wrong end of the curve.

Genzyme will likely show up on next year’s list, depending on how Sanofi manages its financial reporting once their acquisition is closed. It’s a good thing there are some prospects ready to step in and round out the Top 10. I can already see Dendreon in the on-deck circle, getting ready to step up to the plate.
 

Note: a company qualifies as a “Biopharma” if it makes at least 50% of its drug revenues from selling biologics and vaccines. Small-molecule companies need not apply. 
 

—Gil Y. Roth

Editor

Contributors

Editor: Gil Y. Roth

Associate Editor: Kristin Brooks

Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Baxter Bioscience, by Kristin Brooks

The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)

Pipeline information compiled by Kristin Brooks

Revenue information compiled by Gil Roth

Top 10 Biopharmas
based on 2010 revenues, in millions
 

2010 R&D Expenditures